Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis

Abstract

Baseline serum IL-17A correlates moderately with psoriasis severity. Reduction in circulating IL-17A is required for disease remission regardless of therapeutic agent.